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summary of mean and minimum percentage of detectors/pixels 
passing with γ<1 is given in Table 1 for 3%/3mm, 3%/2mm and 
2%/2mm for each system. A lower number indicates greater 
measurement sensitivity. Additionally, ρc, is given for the comparison 
between measured and predicted γ for each system in Table 1. The 
Delta4 was found to be the most sensitive system overall but with the 
lowest ρc, indicating lower agreement with the predicted γ. The 
remaining systems had comparable sensitivity to each other. The 2D-
Array and ArcCHECK measurements exhibited better statistical 
agreement with the predicted γ.  
Conclusions: It is important to understand the sensitivity and 
limitations of the gamma index analysis combined with the equipment 
in use. For the same passing criteria, different devices and software 
combinations exhibit varying sensitivity and agreement with the 
predicted analysis.  
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Purpose/Objective: The use of volumetric arc therapy (VMAT) is 
growing rapidly for many radio-therapy treatments due to its ability to 
quickly deliver highly conformal dose distributions. There has also 
been an increasing interest to use high dose rate flattening filter free 
(FFF) beams as inverse planning systems do not require flat, evenly 
distributed beams. Such fast and complex treatments should be 
accompanied by robust verification. Methods to calibrate electronic 
portal imaging device (EPID) dosimetry has been previously 
documented for step and shoot stereotactic treatments such as 
Intensity modulated radiotherapy (IMRT) using only flattened beams 
and only on the integrated fraction or beam. The aim of this work is 
to provide a time-dependent dose verification method for VMAT that 
can be used with flattened or FFF pre-treatment beams via a general 
calibration model for amorphous silicon (a-Si) EPIDs. 
Materials and Methods: The general calibration model was created 
using a Varian Truebeam, equipped with an as1000 EPID, for each 
unique energy spectrum 6MV, 10MV, 6MV-FFF, 10MV-FFF taking the 
field size, off axis ratio, and penumbral spectral changes of the beam 
into account. Also included in the model are the EPID specific 
corrections such as pixel sensitivity, support arm back scatter, and 
image ghosting. As planned VMAT treatments are separated into 
control points (CPs) for optimization, measured images are also 
separated into the same time intervals so that direct verification of 
prediction images can be performed. Linac log files were used to 
synchronize measurement and prediction. The dosimetric accuracy of 
the calibration model was determined for a range of treatment 
conditions. Measured and predicted 2D control point doses were 
compared using a gamma evaluation with criterion of 3% 3mm. 
Results: Out of 20 VMAT plans tested that passed the clinical action 
level for integrated dose (95% in field area with gamma within 3% 
3mm), the poorest performing plan contained 4.2% in-field area failing 
the gamma criterion when delivered with a flattened beam and 4.0% 
when delivered with a FFF beam. The same plan analysed per control 
point revealed that 18%, and 17% of the arc contained failure areas 
larger than 5% when delivered with a flattened and FFF beam 
respectively. Analysing VMAT treatments per control point reveals 
deviations from predictions during the arc that are averaged in 
integrated doses, and therefore undetectable. For repeated deliveries 
of the same plan, the highest dose variation in delivery of FFF plans 
was ~0.5% compared to 0.2% for flattened beams.  
 
 
Conclusions: The EPID calibration model allows verification of pre-
treatment VMAT doses for both flattened and unflattened beams in a 
time-dependent manner.  
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Purpose/Objective: To develop a method for pre-treatment 
verification of VMAT dose delivery as a function of gantry angle using 
an EPID. 
Materials and Methods: The method: 1) compares MV EPID image 
frames with predicted images at the delivered gantry angles; 2) uses 
an accurate physics-based model that models the EPID images from 
the planned MLC motions and gantry angles; 3) acquires EPID image 
frames using an ancillary frame-grabber system that captures all 
acquired image frames without frame loss; 4) determines the gantry 
angle for the MV image from an accurate encoder-derived gantry 
angle tagged to the header of kV frames (acquired simultaneously 
with the frame-grabber); 5) accounts for small variations in delivered 
gantry angle by a search of a small sub-arc of angles centred on the 
imaged angle to synchronise the measured and predicted images; and 
6) performs Chi comparison of measured and predicted images giving 
these analyses as a function of gantry angle. The method also 
classifies images without significant signal due to beam-holds from 
low signal images using the scatter signal to the kV imager, and we 
have optimised the acquisition frame-rate to reduce image artefact 
due to beam pulse dropping during VMAT delivery. 
Results: The physics-based model was tested for agreement with EPID 
images integrated over the entire treatment with average Chi pass 
rates at 2%,2mm of 99.2% (10% threshold). The accuracy of the gantry 
angle method was tested using images of a phantom to encode the 
true angle on the MV image, with agreement (1 SD) of 0.1 degrees. Chi 
analysis results as a function of angle were assessed for 10 prostate 
patient deliveries. Approximately 650 images were captured during 
each arc delivery, resulting in ~ 100 Chi maps, each representing a 3.5 
degree sub-arc. All Chi pass-rates were greater than 90% at 3%,3mm 
criteria for these images, and more than 90% have a 95% pass-rate, 
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with an average of 97.3% (see Figure 1 for an example of pass-rate vs. 
gantry angle result). Using this method, a problem with the gantry 
motor control with one linac at our centre was found, which was 
corroborated (albeit at a much higher time cost) by commercial VMAT 
QA products, further proving its utility in a clinical setting. 
 
 
Figure 1. Chi results comparing EPID images to predicted images for 
each sub-arc during a complete VMAT delivery. 
 
Conclusions: The method provides a comprehensive and highly 
efficient pre-treatment verification of VMAT delivery using EPID. Dose 
delivery accuracy is assessed as a function of gantry angle to ensure 
accurate treatment. Individual Chi maps for small sub-arcs provide a 
useful tool for error diagnostics.  
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Purpose/Objective: In volumetric-modulated arc therapy (VMAT) 
gantry speed, multileaf collimator configuration, and dose rate vary 
continuously during delivery. For a safe clinical implementation of 
VMAT, accurate 3D dose verification is essential but also complicated. 
In our department, EPID-based in vivo dosimetry using a semi-
empirical back-projection model is clinically employed to verify all 
VMAT treatments. The purpose of this study was to investigate the 
sensitivity of our 3D in vivo EPID dosimetry approach to detecting 
patient-related errors during VMAT delivery. 
Materials and Methods: Treatment planning of VMAT was performed 
using the SmartArc module of the Pinnacle treatment planning 
system. In order to assess the sensitivity of our EPID-based in vivo 
dosimetry method, patient-related errors were simulated by changing 
position and dimension of an anthropomorphic (Alderson) phantom. 
The phantom was irradiated using a 2-arc head-and-neck (6 MV), 
prostate (10 MV) and lung (10MV) VMAT technique. The errors 
comprised a vertical and horizontal phantom shift of 2 cm, a 10 
degree rotation, and the addition of 1cm tissue-equivalent material. 
Dose distributions reconstructed from EPID images and the original 
planned dose distributions were compared using 3D γ evaluation using 
3% dose difference relative to the maximum dose, and 3 mm distance-
to-agreement as criteria.  
Results: Table 1 shows the 3D gamma evaluation of the total dose 
relative to the situation without errors. For the prostate treatment, 
the effect of the introduced errors is negligible, except that the 
reconstructed dose at the prescription point was 4.2% higher for a 
change in thickness of 1 cm. For the head-and-neck treatment, results 
for the gamma evaluation showed a larger sensitivity for the 
introduced errors. Also the dose difference at isocenter for the 
thickness error was larger: -7.8%. The results for the lung plan were 
similar to those for the prostate plan. 
 
 
 
 
 
 
 
 
 
 
Table 1. Gamma Evaluation Results (3%, ±3mm) and Relative Dose 
Differences at Isocenter for Introduced Errors 
Treatment 
Site  Error Type  γmean γ1% 
γ 
≤1(%)  
Relative Dose Difference 
at Isocenter(%)  
Prostate  
Vertical shift 0.41 1.2 96.7  0.8  
Horizontal 
shift  0.30 0.8 99.9  0.4  
Rotation  0.30 0.9 99.5  0.6  
Thickness  0.66 1.4 86.9  -4.2  
Head-and- 
Neck  
Vertical shift 0.90 3.8 69.6  1.1  
Horizontal 
shift  2.23 8.3 36.1  5.1  
Rotation  0.77 3.9 77.5  -1.2  
Thickness  0.81 2.5 72.1  -7.8  
Lung  
Vertical shift 0.42 1.2 97.4  -0.7  
Horizontal 
shift  0.35 1.0 98.9  -1.2  
Rotation  0.49 1.8 92.7  0.1  
Thickness  0.59 1.5 91.9  -7.0 
 
Conclusions: Our verification results show that vertical and horizontal 
shifts and a rotation of the order of 2cm and 10 degree, respectively, 
do not result in significant deviations between EPID reconstructed and 
treatment plan dose distributions for both prostate and lung VMAT 
treatments. The head-and-neck VMAT treatments are more sensitive 
for position errors. With VMAT, EPID dosimetry is often not able to 
detect patient position discrepancies, and should be combined with 
IGRT. However, changes in patient thickness are easily detected.  
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Purpose/Objective: For in vivo verification of IMRT and VMAT 
treatments a 3D dose reconstruction method based on EPID dosimetry 
is routinely applied in our clinic. After reconstruction, the in vivo dose 
is compared to the planned dose by means of a 3D γ analysis. 
Although this method is capable of detecting treatment deviations, 
the clinical relevance of γ parameters is far from obvious. Therefore, 
we wish to correlate the 3D γ evaluation results with other, clinically 
more common parameters used to determine the quality of a dose 
distribution, such as DVH and EUD parameters for specific regions of 
interest (ROIs). As a pilot study, head-and-neck (H&N) VMAT 
treatments were investigated. 
Materials and Methods: 18 treatments were selected having a variety 
of deviations in the in vivo dose, combined with a few treatments 
showing no deviations. For 56 fractions of these treatments, the 3D in 
vivo dose distribution was reconstructed. Several parameters were 
calculated for three different ROIs: the PTV, the volume enclosed by 
the 50% isodose surface and the volume enclosed by the 30% isodose 
surface minus the PTV. These ROIs were chosen to be representative 
for our current clinical portal dosimetry evaluation, and to clearly 
separate high- and low-dose regions. The calculated γ parameters 
were the γ pass rate, 99th percentile of the γ-distribution (γ1%) and 
the mean γ value. Differences between planned and reconstructed 
dose distributions were next evaluated for each ROI using DVH 
parameters D1, D50 and D99 and EUD(1), i.e., the mean dose and 
EUD(7), i.e., focusing on hot spots. Since γ values carry no sign, 
correlations between absolute deviations of DVH and EUD parameters 
and γ parameters were evaluated. 
Results: The table shows the obtained correlation coefficients. For all 
ROIs, strong correlations are observed between γ1%, mean γ and DVH 
and EUD parameters. The D99 parameters, however, hardly correlated 
with anything, except weakly with parameters of the 50% and 30%-PTV 
ROIs. 
 
 
 
 
 
 
